26 recruiting. 26 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 26 | Recruiting 26 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) Dopamine administration, Norepinephrine - Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN) | Phase 4 | Recruiting | University of California, Davis | 30 | 2026-10-30 | 2026-08-18 |
| Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure Hydrocortisone Hemisuccinate: 200 mg per day., reduction of the level of immunosuppression - Sepsis and Septic Shock, Acute Respiratory Failure | Phase 4 | Recruiting | University Hospital, Strasbourg, France | 212 | 2026-08-11 | 2026-08-20 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure Ketone Monoester (KE) - Acute Heart Failure (AHF), Cardiogenic Shock | Phase 4 | Recruiting | Institute for Clinical and Experimental Medicine | 12 | 2026-04-04 | 2026-04-14 |
| Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock Hydrocortisone plus Fludrocortisone, Standard care - Septic Shock | Phase 4 | Recruiting | Northern Jiangsu People's Hospital | 336 | 2026-03-02 | 2026-03-04 |
| Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis Meropenem, Piperacillin/Tazobactam - Sepsis, Septic Shock | Phase 4 | Recruiting | Scandinavian Critical Care Trials Group | 5800 | 2025-06-26 | 2025-07-03 |
| Early Versus Late Adjunctive Vasopressin in Septic Shock vasopressin - early initiation, vasopressin - standard initiation - Sepsis, Septic Shock | Phase 4 | Recruiting | The Cleveland Clinic | 300 | 2025-04-29 | 2026-08-31 |
| Early Angiotensin II in the Emergency Department Angiotensin II Infusion - Septic Shock | Phase 4 | Recruiting | Brett A Faine | 20 | 2025-04-01 | 2026-09-02 |
| Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis Double dosing of beta-lactam antibiotic - Sepsis - to Reduce Mortality in the Intensive Care Unit, Sepsis | Phase 4 | Recruiting | Erasmus Medical Center | 980 | 2025-01-03 | 2025-01-09 |
| Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator Early initiation of continuous renal replacement therapy, Standard initiation of continuous renal replacement therapy - Cardiogenic Shock, Acute Kidney Injury | Phase 4 | Recruiting | Samsung Medical Center | 408 | 2024-12-31 | 2026-01-05 |
| Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial) Indomethacin SR, Placebos - Acute Pancreatitis, Complication | Phase 4 | Recruiting | Peking Union Medical College Hospital | 1504 | 2024-12-01 | 2025-06-15 |
| Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial Iron, EPO, 0.9 % NaCl - Anemia, Sepsis | Phase 4 | Recruiting | Piotr Czempik | 200 | 2024-11-10 | 2024-12-27 |
| The Effect of Dexmedetomidine on the Renal Functions in Septic Critically Ill Patients Dexmedetomidine, Propofol - Sepsis, Septic Shock | Phase 4 | Recruiting | Cairo University | 128 | 2024-10-01 | 2024-10-09 |
| The Preventive Effect of Shenfu Injection on Myocardial Dysfunction in Sepsis Shenfu Injection - Septic Cardiomyopathy, Septic Shock | Phase 4 | Recruiting | First Affiliated Hospital of Wannan Medical College | 440 | 2024-10-01 | 2025-03-27 |
| Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support Enoxaparin Injectable Solution, Argatroban, 1 Mg/mL Intravenous Solution, Unfractionated heparin - Respiratory Insufficiency, Circulatory Failure | Phase 4 | Recruiting | Medical University of Vienna | 90 | 2024-07-30 | 2024-10-29 |
| Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery Vasopressin intravenous infusion, Norepinephrine intravenous infusion - Vasoplegic Syndrome of Cardiac Surgery | Phase 4 | Recruiting | University of Sao Paulo | 350 | 2024-04-01 | 2025-04-30 |
| Early Administration of Norepinephrine in Sepsis Norepinephrine Bitartrate, Placebo - Sepsis, Severe | Phase 4 | Recruiting | Tunis University | 200 | 2023-08-01 | 2024-12-04 |
| Central Line Study Central venous catheter insertion - Shock | Phase 4 | Recruiting | Montefiore Medical Center | 160 | 2022-11-16 | 2026-01-06 |
| Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator Culprit lesion only PCI, Immediate multi-vessel PCI - Cardiogenic Shock, Acute Myocardial Infarction | Phase 4 | Recruiting | Samsung Medical Center | 560 | 2022-11-16 | 2024-11-06 |
| Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction Reduced noradrenaline use - Cardiogenic Shock, Myocardial Infarction | Phase 4 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 776 | 2022-10-01 | 2026-03-27 |
Showing 20 of 26. Sign in to see all of them.
Shock, Septic (11) · Sepsis (7) · Shock, Cardiogenic (6) · Acute Kidney Injury (2) · Diabetes Insipidus (2) · Hemorrhage (2) · Respiratory Insufficiency (2) · Anemia (1) · Atrial Fibrillation (1) · Carcinoma, Non-Small-Cell Lung (1) · Critical Illness (1) · Cytokine Release Syndrome (1) · Heart Failure (1) · Hypertension, Pulmonary (1)
Pathologic Processes (26) · Pathological Conditions, Signs and Symptoms (26) · Inflammation (13) · Systemic Inflammatory Response Syndrome (12) · Cardiovascular Diseases (11) · Infections (11) · Vascular Diseases (10) · Heart Diseases (7) · Infarction (6) · Ischemia (6) · Myocardial Ischemia (6) · Necrosis (6) · Myocardial Infarction (5) · Female Urogenital Diseases (4)
Norepinephrine (4) · Vasopressins (3) · Albumins (1) · Arginine Vasopressin (1) · Crystalloid Solutions (1) · Dexmedetomidine (1) · Dobutamine (1) · Epinephrine (1) · Fludrocortisone (1) · Heparin (1) · Hydrocortisone (1) · Iron (1) · Meropenem (1) · Midodrine (1) · Milrinone (1)
Samsung Medical Center (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Asan Medical Center (1) · Brett A Faine (1) · Cairo University (1) · Erasmus Medical Center (1) · First Affiliated Hospital of Wannan Medical College (1) · Institute for Clinical and Experimental Medicine (1) · Medical University of Vienna (1) · Montefiore Medical Center (1) · Northern Jiangsu People's Hospital (1) · Ottawa Heart Institute Research Corporation (1) · Peking Union Medical College Hospital (1) · Pharmazz, Inc. (1) · Piotr Czempik (1)
United States (7) · China (3) · South Korea (3) · Canada (2) · Netherlands (2) · Austria (1) · Brazil (1) · Czechia (1) · Denmark (1) · Egypt (1) · France (1) · Greece (1) · India (1) · Poland (1) · Tunisia (1)
Ahlem Trifi (1) · Amany M Mohamed, Ph.D (1) · Baofeng Zhu, MD (1) · Benjamin J Friedman, MD (1) · Daoyuan Jing, MD (1) · Deepika Sankaran, MD (1) · Dong Wu, M.D. (1) · Gretchen L. Sacha, PharmD (1) · Hong Liu, MD (1) · Jeong Hoon Yang, MD (1) · Jianzhong Yang, MD (1) · Johannes Gratz, PD, MD, PhD (1) · John P Kress, MD (1) · Kanzy M Hassan, B. Pharm (1)
PMID 25872171, PMID 34582425, PMID 35246227, PMID 38999331, PMID 39024364, PMID 40119275, PMID 42674465
2023 (1)